Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Ischemic Heart Disease

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 161 articles: HTML format

Single Articles

April 2026
1. IBANEZ B, Jernberg T, Atar D
   Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. Reply.
   N Engl J Med. 2026;394:1660-1661.
   PubMed    
   
   
   
2. OMEROVIC E
   Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
   N Engl J Med. 2026;394:1660.
   PubMed    
   
   
   
3. TURGEON R
   Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
   N Engl J Med. 2026;394:1659-1660.
   PubMed    
   
   
   
4. BOHULA EA, Giugliano RP, Sabatine MS
   Evolocumab for Primary Prevention of Cardiovascular Disease. Reply.
   N Engl J Med. 2026;394:1658-1659.
   PubMed    
   
   
   
5. BUDOFF MJ, Iskander B
   Evolocumab for Primary Prevention of Cardiovascular Disease.
   N Engl J Med. 2026;394:1658.
   PubMed    
   
   
   
6. GARCIA DE TENA J, Morales-Ortega A, Bernal-Bello D
   Evolocumab for Primary Prevention of Cardiovascular Disease.
   N Engl J Med. 2026;394:1658.
   PubMed    
   
   
   
7. KJELDSEN SE, Kreutz R, Mancia G
   Evolocumab for Primary Prevention of Cardiovascular Disease.
   N Engl J Med. 2026;394:1657-1658.
   PubMed    
   
   
   
8. PIRIS GONZALEZ M, Ortiz A
   Evolocumab for Primary Prevention of Cardiovascular Disease.
   N Engl J Med. 2026;394:1656-1657.
   PubMed    
   
   
   
9. LIN S, He Y, He L, Liu Y, et al
   Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.
   N Engl J Med. 2026;394:1480-1490.
   PubMed     Abstract available
   
   
   
10. SHARMA M, Dong Q, Hirano T, Kasner SE, et al
    Asundexian for Secondary Stroke Prevention.
    N Engl J Med. 2026;394:1467-1479.
    PubMed     Abstract available
    
    
    
11. NICHOLLS SJ, Pavo I, D'Alessio D
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.
    N Engl J Med. 2026;394:10.
    PubMed    
    
    
    
12. ANKER MS, Butler J, Anker SD
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551-1553.
    PubMed    
    
    
    
13. XU H, Cong X, Lin L
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    PubMed    
    
    
    
14. VAN BRUGGEN F
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    PubMed    
    
    
    
15. BECATTINI C, Agnelli G, Paciaroni M
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550-1551.
    PubMed    
    
    
    
16. CHUAN F, Gao Y, Zhou B
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550.
    PubMed    
    
    
    
17. SKEITH L, Bates SM
    Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk.
    N Engl J Med. 2026;394:1514-1528.
    PubMed     Abstract available
    
    
    
18. CHOI KH, Kang D, Kim W, Doh JH, et al
    Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
    N Engl J Med. 2026;394:1302-1312.
    PubMed     Abstract available
    
    
    March 2026
19. TESTA L, De la Torre Hernandez JM, De Maria GL, Jones DA, et al
    IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600440.
    PubMed     Abstract available
    
    
    
20. WELT F
    Seeing the Left Main Coronary Artery Clearly - Is IVUS Always Necessary?
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMe2602959.
    PubMed    
    
    
    
21. DAEMEN J, van der Eijk JA, Barbierato M, Byrne RA, et al
    Angiography-Based Physiology to Guide Coronary Revascularization.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2601841.
    PubMed     Abstract available
    
    
    
22. PERERA D, Ryan M, Ezad SM, Khan SQ, et al
    Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2515704.
    PubMed     Abstract available
    
    
    
23. LEE YJ, Lee SJ, Kim JW, Lee SH, et al
    Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
    N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2600283.
    PubMed     Abstract available
    
    
    
24. GUIMARAES PO, Franken M, Lemos PA
    Aspirin after PCI in Acute Coronary Syndromes. Reply.
    N Engl J Med. 2026;394:1036-1037.
    PubMed    
    
    
    
25. CHAN SCH
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1036.
    PubMed    
    
    
    
26. LI M, Zhang G, Liu X
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035-1036.
    PubMed    
    
    
    
27. STRASSMEIR ML, Baumer U, Niessner A
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035.
    PubMed    
    
    
    
28. FEARON WF
    Assessing Nonculprit Coronary-Artery Lesions in STEMI.
    N Engl J Med. 2026;394:1021-1022.
    PubMed    
    
    
    February 2026
29. CEREDA A, Stracqualursi M, Lucreziotti S
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821-822.
    PubMed    
    
    
    
30. MUNKHAUGEN J, Atar D, Prescott E
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:824-825.
    PubMed    
    
    
    
31. IBANEZ B, Latini R, Rossello X
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:823-824.
    PubMed    
    
    
    
32. ZIEMINSKI JJ, Bell MR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822-823.
    PubMed    
    
    
    
33. GAMARDELLA M, Ciconte G, Pappone C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822.
    PubMed    
    
    
    
34. LLOP D, Turu M, Llop C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821.
    PubMed    
    
    
    
35. CHI KY, Mangalesh S, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820-821.
    PubMed    
    
    
    
36. RAHHAL A, Al Hijji M, Arabi AR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820.
    PubMed    
    
    
    
37. LIP GYH, Kuzma L
    Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:713-715.
    PubMed    
    
    
    
38. LUSCHER TF, Wenzl FA
    Beta-Blockers after Myocardial Infarction - Toward Personalized Management.
    N Engl J Med. 2026;394:599-602.
    PubMed    
    
    
    
39. SCHUNKERT H, Natarajan P, Samani NJ
    The Inherited Basis of Coronary Artery Disease.
    N Engl J Med. 2026;394:576-587.
    PubMed     Abstract available
    
    
    January 2026
40. RYAN SJ, Jorstad OK, Skjelland M, Pesonen M, et al
    A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion.
    N Engl J Med. 2026;394:442-450.
    PubMed     Abstract available
    
    
    
41. THIELE H, Hassager C
    Cardiogenic Shock.
    N Engl J Med. 2026;394:62-77.
    PubMed     Abstract available
    
    
    December 2025
42. NICHOLLS SJ, Pavo I, Bhatt DL, Buse JB, et al
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    N Engl J Med. 2025;393:2409-2420.
    PubMed     Abstract available
    
    
    November 2025
43. LEOPOLD JA
    Discontinuation of Aspirin in Acute Coronary Syndromes Treated with Coronary-Artery Stents.
    N Engl J Med. 2025;393:2164-2166.
    PubMed    
    
    
    
44. KRISTENSEN AMD, Rossello X, Atar D, Yndigegn T, et al
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2025 Nov 9. doi: 10.1056/NEJMoa2512686.
    PubMed     Abstract available
    
    
    
45. BOHULA EA, Marston NA, Bhatia AK, De Ferrari GM, et al
    Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2514428.
    PubMed     Abstract available
    
    
    
46. LEE SJ, Yu HT, Lee YJ, Lee SH, et al
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512091.
    PubMed     Abstract available
    
    
    
47. LOK CE, Farkouh M, Hemmelgarn BR, Moist LM, et al
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2025 Nov 7. doi: 10.1056/NEJMoa2513032.
    PubMed     Abstract available
    
    
    October 2025
48. NIJVELDT R, Maeng M, Beijnink CWH, Piek JJ, et al
    Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
    N Engl J Med. 2025 Oct 28. doi: 10.1056/NEJMoa2512918.
    PubMed     Abstract available
    
    
    September 2025
49. MAGNUSSEN C, Lorenz T, Blankenberg S
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. Reply.
    N Engl J Med. 2025;393:1247-1248.
    PubMed    
    
    
    
50. CORDERO L, Abasheva D, Ortiz A
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246-1247.
    PubMed    
    
    
    
51. AKBARPOUR S, Azizpour Y, Larijani B
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246.
    PubMed    
    
    
    
52. ZHENG X, Zhang J, Li Z
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245-1246.
    PubMed    
    
    
    
53. COOPER KH
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245.
    PubMed    
    
    
    
54. NICHOLLS SJ, Nelson AJ, Ray KK
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Reply.
    N Engl J Med. 2025;393:928.
    PubMed    
    
    
    
55. GUO M, Liu Z
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927-928.
    PubMed    
    
    
    
56. ZHANG D, Wu H, Gong S
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927.
    PubMed    
    
    
    
57. MODARRESSI T
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:926-927.
    PubMed    
    
    
    
58. JEPPSSON A, James S, Moller CH, Malm CJ, et al
    Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
    N Engl J Med. 2025 Sep 1. doi: 10.1056/NEJMoa2508026.
    PubMed     Abstract available
    
    
    August 2025
59. TARANTINI G, Honton B, Paradies V, Lemesle G, et al
    Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2508808.
    PubMed     Abstract available
    
    
    
60. LEMESLE G, Didier R, Steg PG, Simon T, et al
    Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507532.
    PubMed     Abstract available
    
    
    
61. GUIMARAES PO, Franken M, Tavares CAM, Antunes MO, et al
    Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507980.
    PubMed     Abstract available
    
    
    
62. MUNKHAUGEN J, Kristensen AMD, Halvorsen S, Holmager T, et al
    Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2505985.
    PubMed     Abstract available
    
    
    
63. IBANEZ B, Latini R, Rossello X, Dominguez-Rodriguez A, et al
    Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2504735.
    PubMed     Abstract available
    
    
    
64. TONET E, Raisi A, Zagnoni S, Chiaranda G, et al
    Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
    N Engl J Med. 2025 Aug 29. doi: 10.1056/NEJMoa2502799.
    PubMed     Abstract available
    
    
    
65. MCGUIRE DK, David JP, Inzucchi SE
    Oral Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2025;393:725.
    PubMed    
    
    
    
66. DOS SANTOS MCF, de Lima NN, Lima JG
    Oral Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2025;393:724-725.
    PubMed    
    
    
    July 2025
67. MENSAH GA
    Estimates of Cardiovascular Risks and Benefits - When Knowing Is Not Enough.
    N Engl J Med. 2025;393:187-189.
    PubMed    
    
    
    June 2025
68. DAKIK HA
    Aspiration Thrombectomy for Coronary Stent Thrombosis.
    N Engl J Med. 2025;392:e52.
    PubMed    
    
    
    May 2025
69. JOLLY SS, d'Entremont MA, Mian R
    Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:2075.
    PubMed    
    
    
    
70. JOLLY SS, d'Entremont MA, Lee SF
    Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:2074-2075.
    PubMed    
    
    
    
71. GOLINO M, Van Tassell B, Abbate A
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2073-2074.
    PubMed    
    
    
    
72. KIDA Y
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2073.
    PubMed    
    
    
    
73. GU HQ, Jiang Y, Li H
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2072-2073.
    PubMed    
    
    
    
74. VAN TWIST DJL, Appelboom Y
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2072.
    PubMed    
    
    
    
75. STRIESSNIG J
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2071-2072.
    PubMed    
    
    
    
76. ZANNAD F
    Seeking Multiorgan Benefits with Cardiovascular-Kidney-Metabolic Drug Therapy.
    N Engl J Med. 2025;392:2061-2062.
    PubMed    
    
    
    
77. QIU Z, Li F, Sang H, Yuan G, et al
    Intravenous Tenecteplase before Thrombectomy in Stroke.
    N Engl J Med. 2025 May 21. doi: 10.1056/NEJMoa2503867.
    PubMed     Abstract available
    
    
    
78. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
    PubMed     Abstract available
    
    
    
79. RADER DJ
    Targeting Lipoprotein(a) - the Next Frontier in Cardiovascular Disease.
    N Engl J Med. 2025;392:1740-1742.
    PubMed    
    
    
    March 2025
80. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    
81. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
    N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
    PubMed     Abstract available
    
    
    
82. KOTANIDIS CP, Maron DJ, Jernberg T
    Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?
    N Engl J Med. 2025;392:1234-1236.
    PubMed    
    
    
    February 2025
83. RIDKER PM, Buring JE
    Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply.
    N Engl J Med. 2025;392:828.
    PubMed    
    
    
    
84. PEI C, Zhang W, Huang J
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:828.
    PubMed    
    
    
    
85. GUI C, Huang Y
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:827-828.
    PubMed    
    
    
    
86. CHO MS, Nam GB, Park DW
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease. Reply.
    N Engl J Med. 2025;392:826-827.
    PubMed    
    
    
    
87. SHIMAZU Y
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    PubMed    
    
    
    
88. GREMMEL T
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    PubMed    
    
    
    
89. KAWAI T, Williams WW, Elias N, Fishman JA, et al
    Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2412747.
    PubMed     Abstract available
    
    
    January 2025
90. SILVAIN J, Vicaut E, Montalescot G
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:100-101.
    PubMed    
    
    
    
91. CHI KY, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    
92. GASOWSKI J, Perera I, Piotrowicz K
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    
93. VAN VOLLENHOVEN RF
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    PubMed    
    
    
    December 2024
94. PURI R
    The Art and Science of Managing Stable Coronary Artery Disease in Patients Undergoing TAVI.
    N Engl J Med. 2024;391:2267-2268.
    PubMed    
    
    
    
95. SALEH Y, Rios S
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2024;391:e54.
    PubMed    
    
    
    November 2024
96. FIORELLA D, Monteith SJ, Hanel R, Atchie B, et al
    Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
    N Engl J Med. 2024 Nov 20. doi: 10.1056/NEJMoa2409845.
    PubMed     Abstract available
    
    
    
97. JOLLY SS, d'Entremont MA, Lee SF, Mian R, et al
    Colchicine in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405922.
    PubMed     Abstract available
    
    
    
98. JOLLY SS, d'Entremont MA, Pitt B, Lee SF, et al
    Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923.
    PubMed     Abstract available
    
    
    
99. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMe2414472.
    PubMed    
    
    
    
100. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
     Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
     N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2409501.
     PubMed     Abstract available
     
     
     October 2024
101. HEATON K, Zern EK, Spahillari A, Barrett CD, et al
     Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction.
     N Engl J Med. 2024;391:1633-1641.
     PubMed    
     
     
     
102. ALKAISSI H, Nazari MA, Hadrava Vanova K, Uher O, et al
     Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma.
     N Engl J Med. 2024;391:1552-1555.
     PubMed    
     
     
     
103. JERNBERG T
     Routine Beta-Blockers in Secondary Prevention - Approaching Retirement?
     N Engl J Med. 2024;391:1356-1357.
     PubMed    
     
     
     September 2024
104. HABIB M, Aronson D
     Electrocardiographic Findings in Diffuse Subendocardial Ischemia.
     N Engl J Med. 2024;391:e19.
     PubMed    
     
     
     
105. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410900.
     PubMed    
     
     
     
106. KUNADIAN V, Mossop H, Shields C, Bardgett M, et al
     Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791.
     PubMed     Abstract available
     
     
     
107. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410903.
     PubMed    
     
     
     
108. LIP GYH
     Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696.
     PubMed    
     
     
     
109. CHO MS, Kang DY, Ahn JM, Yun SC, et al
     Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
     N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362.
     PubMed     Abstract available
     
     
     August 2024
110. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2410895.
     PubMed    
     
     
     
111. BLUMENTHAL RS, Martin SS
     Prevention of Cardiovascular Disease - Don't Stop Thinking about Tomorrow.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080.
     PubMed    
     
     
     
112. RIDKER PM, Moorthy MV, Cook NR, Rifai N, et al
     Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182.
     PubMed     Abstract available
     
     
     
113. LONBORG J, Jabbari R, Sabbah M, Veien KT, et al
     PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
     N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2401513.
     PubMed     Abstract available
     
     
     
114. SILVAIN J, Cayla G, Ferrari E, Range G, et al
     Beta-Blocker Interruption or Continuation after Myocardial Infarction.
     N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204.
     PubMed     Abstract available
     
     
     
115. RUBIN EJ, Leopold J, Morrissey S
     NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial Infarction.
     N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2410891.
     PubMed    
     
     
     
116. MAHENDIRAN T, Collet C, De Bruyne B
     More on Coronary-Artery Autoregulation with Increasing Stenosis. Reply.
     N Engl J Med. 2024;391:671.
     PubMed    
     
     
     
117. YANG X, Wu M, Zhang G
     More on Coronary-Artery Autoregulation with Increasing Stenosis.
     N Engl J Med. 2024;391:670-671.
     PubMed    
     
     
     July 2024
118. BOHM F, James S
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
     N Engl J Med. 2024;391:288.
     PubMed    
     
     
     
119. LI P
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
     N Engl J Med. 2024;391:287-288.
     PubMed    
     
     
     
120. YNDIGEGN T, Hofmann R, Jernberg T
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
     N Engl J Med. 2024;391:95.
     PubMed    
     
     
     
121. KOMAMURA K, Kobayashi K, Iwase M
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024;391:94-95.
     PubMed    
     
     
     
122. CLELAND JGF, McMurray JJV, Freemantle N
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024;391:94.
     PubMed    
     
     
     June 2024
123. MOLLER JE, Hassager C
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
     N Engl J Med. 2024;390:2328-2330.
     PubMed    
     
     
     
124. VON LEWINSKI D, Herold L, Toth GG
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2328.
     PubMed    
     
     
     
125. BALDETTI L, Pieri M, Scandroglio AM
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2328.
     PubMed    
     
     
     
126. ELKARYONI A, Hyder O, Saad M
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2327.
     PubMed    
     
     
     
127. FROM AM
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2327.
     PubMed    
     
     
     
128. MALLIDI J, Lotfi A
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2326-2327.
     PubMed    
     
     
     
129. THIELE H, Desch S, Zeymer U
     Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:2325-2326.
     PubMed    
     
     
     
130. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
     Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
     N Engl J Med. 2024;390:2227.
     PubMed    
     
     
     
131. MAAHS DM, Svensson J
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:2226-2227.
     PubMed    
     
     
     
132. WENSTEDT EFE, Vogt L
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:2226.
     PubMed    
     
     
     
133. LI S, Gu HQ, Li H, Wang X, et al
     Reteplase versus Alteplase for Acute Ischemic Stroke.
     N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
     PubMed     Abstract available
     
     
     
134. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
     Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
     N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
     PubMed     Abstract available
     
     
     
135. MAHENDIRAN T, Collet C, De Bruyne B
     Coronary-Artery Autoregulation with Increasing Stenosis.
     N Engl J Med. 2024;390:2030-2032.
     PubMed    
     
     
     May 2024
136. KING G, Hamilton GW
     Left Ventricular Thrombus after Anterior Myocardial Infarction.
     N Engl J Med. 2024;390:e50.
     PubMed    
     
     
     
137. NATARAJAN P
     Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
     N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
     PubMed    
     
     
     
138. ALBERS GW, Purdon B, Campbell BCV
     Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
     N Engl J Med. 2024;390:1729.
     PubMed    
     
     
     
139. GOYAL M, Bosshart SL, Ospel JM
     Tenecteplase for Stroke at 4.5 to 24 Hours.
     N Engl J Med. 2024;390:1729.
     PubMed    
     
     
     
140. GRINSPOON SK, Ribaudo HJ, Douglas PS
     Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
     N Engl J Med. 2024;390:1626-1628.
     PubMed    
     
     
     April 2024
141. STEG PG
     Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
     N Engl J Med. 2024;390:1434-1436.
     PubMed    
     
     
     
142. RAO SV
     Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
     N Engl J Med. 2024;390:1436-1438.
     PubMed    
     
     
     
143. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
     Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
     N Engl J Med. 2024;390:1382-1393.
     PubMed     Abstract available
     
     
     
144. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
     FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
     N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
     PubMed     Abstract available
     
     
     
145. KUNADIAN V
     Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
     N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
     PubMed    
     
     
     
146. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
     Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
     N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
     PubMed     Abstract available
     
     
     
147. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
     Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
     N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
     PubMed     Abstract available
     
     
     
148. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
     Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
     PubMed     Abstract available
     
     
     
149. ROULEAU J
     Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
     PubMed    
     
     
     
150. BUTLER J, Jones WS, Udell JA, Anker SD, et al
     Empagliflozin after Acute Myocardial Infarction.
     N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
     PubMed     Abstract available
     
     
     
151. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
     Prevention of Cardiovascular Disease in Type 1 Diabetes.
     N Engl J Med. 2024;390:1207-1217.
     PubMed    
     
     
     March 2024
152. WHITE HD
     A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
     N Engl J Med. 2024;390:10.
     PubMed    
     
     
     
153. AL-LAMEE RK, Rajkumar CA
     A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
     N Engl J Med. 2024;390:1151-1152.
     PubMed    
     
     
     
154. DURANTE A, Baiardo Redaelli M
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1150-1151.
     PubMed    
     
     
     
155. SHERROD CF 4TH, O'Keefe EL, Ikemura N
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1150.
     PubMed    
     
     
     
156. BESTERMANN WH JR
     A Placebo-Controlled Trial of PCI for Stable Angina.
     N Engl J Med. 2024;390:1149-1150.
     PubMed    
     
     
     
157. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
     Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
     N Engl J Med. 2024;390:1030-1043.
     PubMed    
     
     
     
158. CARSON JL, Brooks MM, Hebert PC
     Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
     N Engl J Med. 2024;390:961-962.
     PubMed    
     
     
     
159. KHAN MS, Spertus JA, Chan PS
     Transfusion Strategy in Myocardial Infarction and Anemia.
     N Engl J Med. 2024;390:960-961.
     PubMed    
     
     
     
160. CHAPALAIN X, Aubron C
     Transfusion Strategy in Myocardial Infarction and Anemia.
     N Engl J Med. 2024;390:960.
     PubMed    
     
     
     
161. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
     Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
     N Engl J Med. 2024;390:900-910.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum